Clinical Trials Logo

Clinical Trial Summary

A multicenter, randomized, double-blind, placebo-controlled clinical trial was designed. The study included two experimental groups (low-dose ZKY001 eye drops group and medium-dose ZKY001 eye drops group) and a placebo control group, with 60 subjects in each group.


Clinical Trial Description

Each subject had the study drug instilled into the study eye according to the randomly obtained drug number. Duration OF THE STUDY:The screening period was D-5 to D-1, the experimental period was D0 (the day of operation) to D5, and the observation period was D10±2. Statistical analyses were performed with the use of SAS software (version 9.4 or higher) without special instructions. All statistical tests were two-sided, with a significance level of 0.05. Enrollment analysis: the number of enrolled and completed cases in each center was summarized, and the list of dropped cases was made. Overall dropout rates in each group and dropout rates related to adverse events were compared between groups with the use of the chi-square test or Fisher's exact test. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06213727
Study type Interventional
Source Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
Contact
Status Completed
Phase Phase 2
Start date March 15, 2022
Completion date November 14, 2022

See also
  Status Clinical Trial Phase
Completed NCT00238862 - Treatment of PED With AMT and Autologous Serum N/A
Completed NCT01075347 - Topical Autologous Serum Application for the Treatment of Corneal Epithelium Defect After Ocular Surgeries Phase 1
Active, not recruiting NCT01168375 - The Role of Umbilical Cord Serum Therapy on Improvement of Corneal Epithelial Defect Following Diabetic Vitrectomy Phase 1